Merck (MRK) Tops Q3 EPS by 8c, Lifts FY EPS Gudiance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St stocks end higher with major corporate earnings in view
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
- Tesla expands price cuts to China, Germany after reducing FSD cost; shares down
- Gold prices slide as M.East fears ease, rate jitters persist
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'
October 30, 2017 10:45 AM EDTUBS lowered its price target on Merck (NYSE: MRK) to $67.00 (from $72.00) while maintaining a Buy rating, following the announcement that management would push out results into early 2019 for Keynote-189 in lung cancer.
Analyst Marc Goodman notes a cautious outlook on the shares as... More
Merck (MRK) PT Lowered to $69 at Leerink Partners
October 30, 2017 7:49 AM EDTLeerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results
Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.
... MoreMorgan Stanley Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:11 AM EDTMorgan Stanley downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $56.00 (from $69.00).
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $58.24 Friday.
... MoreBarclays Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:05 AM EDTBarclays downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $62.00 (from $72.00).
Analyst Geoff Meacham cites limited upside potential for the equity originating from Keytruda which is "by far Meerck's biggest value driver." The analyst notes headwinds to the... More
